跳至主要内容
临床试验/NL-OMON22587
NL-OMON22587已完成不适用

An open label, randomised comparative trial of 5 years adjuvant exemestane treatment versus tamoxifen for 2½-3 years followed by 2½-2 years of exemestane, for a total of 5 years as adjuvant treatment in postmenopausal women with early breast cancer.

Erasmus Medical Center - Daniel den Hoed Cancer CenterP.O. Box 52013008 AE ROTTERDAM0 个研究点目标入组 9,000 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
9,000

研究概览

简要总结

/A

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Histologically/cytologically confirmed adenocarcinoma of the breast, followed by intended curative surgery (R0) and if indicated, also radiotherapy;
  • 2. Any Tumor with a size > 3 cm, or Any N+ or tumor size 1-3 cm, N0 and one of the following factors: MAI > 10, Bloom-Richardson: grade 3, Any TNM stage BC considered to receive adjuvant hormonal therapy, as agreed by NABON-NVMO;

排除标准

  • 1. Inflammatory breast cancer, positive supraclavicular nodes, ulceration/infiltration of local skin metastasis;
  • 2. Both ER negative and PgR negative primary tumor;

研究者

发起方
Erasmus Medical Center - Daniel den Hoed Cancer CenterP.O. Box 52013008 AE ROTTERDAM

相似试验